USA - NASDAQ:TSRO - US8815691071
The current stock price of TSRO is 74.96 null. In the past month the price increased by 2.84%. In the past year, price increased by 17.29%.
Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.
TESARO INC
1000 WINTER STREET
WALTHAM MA 02451
CEO: Leon O. MoulderJr.
Phone: 339-970-0900
The current stock price of TSRO is 74.96 null. The price increased by 0.03% in the last trading session.
The exchange symbol of TESARO INC is TSRO and it is listed on the Nasdaq exchange.
TSRO stock is listed on the Nasdaq exchange.
TESARO INC (TSRO) has a market capitalization of 4.13B null. This makes TSRO a Mid Cap stock.
TESARO INC (TSRO) has a support level at 72.69 and a resistance level at 74.97. Check the full technical report for a detailed analysis of TSRO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TSRO does not pay a dividend.
TESARO INC (TSRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.86).
ChartMill assigns a technical rating of 8 / 10 to TSRO. When comparing the yearly performance of all stocks, TSRO is one of the better performing stocks in the market, outperforming 97.74% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to TSRO. Both the profitability and financial health of TSRO have multiple concerns.
Over the last trailing twelve months TSRO reported a non-GAAP Earnings per Share(EPS) of -11.86. The EPS decreased by -40.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -295.67% | ||
ROA | -91.25% | ||
ROE | 495.92% | ||
Debt/Equity | -3.75 |